Article
Federal Circuit: A Biosimilar Applicant Must Provide Notice Of Intent To Market A Biosimilar Product, No Exceptions
Notably, the Federal Circuit took the opportunity to defend its previous holding in Amgen v. Sandoz that notice of intent to commercially market cannot be provided until the FDA approves the biosimilar product.
Fenwick
